NK (EGFR)

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

Bispecific EGFR/CD16 antigen-binding protein
US 11510972 B2Applicant: AFFIMED GMBHPriority: 2018
CN
US
WO
5 publications
TREATMENT OF CANCER WITH NK CELLS AND AN EGFR TARGETED ANTIBODY
US 2024366664 A1Applicant: ARTIVA BIOTHERAPEUTICS INCPriority: 2021
CN
US
3 publications
Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
US 11230699 B2Applicant: NANTKWEST INCPriority: 2020
US
3 publications
COMBINATION CANCER THERAPY WITH MEMORY NK CELLS AND ANTI-CANCER BISPECIFIC MOLECULES
US 20240358759 A1Applicant: WUGEN INCPriority: 2021
CN
US
2 publications
NK CELL ENGAGERS BINDING TO NKP80 AND USES THEREOF
EP 4705348 A1Applicant: AGENCY SCIENCE TECH & RESPriority: 2023
EP
WO
2 publications
Use of NK-1 receptor antagonists for treating hypomagnesemia, neurogenic inflammation, and cardiac dysfunction associated with EGFR-blocking drugs
US 9474761 B2Applicant: WEGLICKI WILLIAM BPriority: 2015
US
2 publications
Anti-EGFR combination for tumor treatment
CN 106943597 AApplicant: BIRDIE BIOTECH INCPriority: 2016
CN
2 publications
Method for preparing EGFR CAR-NK cells based on polypeptide gel droplet confinement transfection technology and application of EGFR CAR-NK cells
CN 122146614 AApplicant: UNIV GUIZHOU MEDICALPriority: 2026
CN
2 publications
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
US 2006035893 A1Applicant: BOEHRINGER INGELHEIM INTPriority: 2004
US
ANTI-EGFR/HIGH AFFINITY NK-CELLS COMPOSITIONS AND METHODS FOR CHORDOMA TREATMENT
CN 110612121 AApplicant: NANTKWEST INCPriority: 2017
CN